MITOMYCIN C
Solid Tumor Cancer
Sarcoma Oncology Research Center, LLCSmall moleculePhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 73/ 100
Competitive context
42 Active assets in the Solid Tumor Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Sarcoma Oncology Research Center, LLC | Phase 2 | CCC |
DEXAMETHASONE GlaxoSmithKline | Phase 3 | CCC |
Casopitant GlaxoSmithKline | Phase 3 | CCC |
Zofran GlaxoSmithKline | Phase 3 | CCC |
Thalidomide Sarcoma Oncology Research Center, LLC | Phase 2 | CCC |
View all 50 →
Same molecule, other indications
MITOMYCIN C is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →